Evidently, Skp2-deficiency is more effective in increasing cisplatin cytotoxicity in cisplatin-resistant cells than the inhibition of ATM, suggesting Skp2 is likely to be a more promising target than ATM in the treatment of cisplatin-resistant mantle cell lymphoma (MCL) [32]. Here, SKP2 is linked to mantle cell lymphoma.